The FDA has accepted and filed Nanoscope Therapeutics’ biologics license application (BLA) for Mogenry (sonpiretigene isteparvovec; MCO-010), an investigational optogenetic gene therapy designed to restore vision in patients with retinitis pigmentosa (RP) and severe vision loss.
Source: eyewire